Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, briefly discusses novel strategies that may be used to effectively target leukemic stem cells when treating patients with acute myeloid leukemia (AML). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.